Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | PTPRB | P23467 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618193 | 0.86 | JAK2 (0.59) | JAK2JAK1HSD11B1GPR119STS | |
| SCHEMBL13853353 | 0.84 | OPRM1 (0.60) | JAK2JAK1HSD11B1GPR119STS | |
| SCHEMBL3012474 | 0.83 | JAK2 (0.62) | JAK2JAK1HSD11B1GPR119STS | |
| SCHEMBL1624526 | 0.82 | HSD11B1 (0.66) | JAK2JAK1HSD11B1GPR119STS | |
| SCHEMBL2966618 | 0.82 | DCUN1D1 (0.57) | JAK2JAK1DCUN1D1 | |
| SCHEMBL803527 | 0.82 | JAK2 (0.74) | JAK2JAK1HSD11B1GPR119STS | |
| SCHEMBL5567646 | 0.81 | GPR119 (0.46) | GPR119 | |
| SCHEMBL3764740 | 0.80 | JAK2 (0.52) | JAK2JAK1HSD11B1GPR119STS | |
| SCHEMBL7136590 | 0.79 | CCR5 (0.55) | JAK2JAK1STS | |
| SCHEMBL12122824 | 0.79 | JAK2 (0.58) | JAK2JAK1HSD11B1GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238694-B2 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1781670-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | Cumbre Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1723150-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006012470-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | CUMBRE PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019985-A1 | Rifamycin derivatives | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005070941-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019985-A1 | Rifamycin derivatives | RIF1, NQO1, MRM1 | JAK2 4431/4885JAK1 4187/4885HSD11B1 907/4885 |
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | RIF1, TOP1, TOP2A | JAK2 4624/4885JAK1 4702/4885HSD11B1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.